The present application provides high solids film coating compositions comprising a water-soluble cellulose ether, hydroxy propyl cellulose (HPC), a poly (N-vinyl pyrrolidone-co-vinyl acetate) copolymer, a film-forming agent based on D-glucose, plasticizer, medium chain triglycerides (MCT) and an anti-tack agent. The invention further provides a process for preparing the above described film coating compositions and method of coating solid substrate with such coating compositions.

The present disclosure relates to a pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, and particularly to a pharmaceutical composition which exhibits a dual release profile of immediate release and sustained release so that long-term efficacy can be sustained. The pharmaceutical composition containing esomeprazole or a pharmaceutically acceptable salt thereof and with a dual release profile, according to the present disclosure, can secure bioavailability equivalent to that of existing esomeprazole immediate-release/enteric-release formulations, and can maintain long-term efficacy due to the dual release profile thereof even when administered once a day, thus preventing the occurrence of nocturnal acid breakthrough, and accordingly, can be effectively used as a therapeutic agent for nocturnal acid breakthrough.

Disclosed are dosage forms and kits that support the human body during a stress response. The dosages forms can include at least one sensory disrupter, at least one stress-buster and at least one calming reliever. In embodiments, the dosage form can include at least one nervous system component, at least one immune system component, and at least one endocrine system component. Also disclosed are kits containing the dosage forms and methods of preparation and use of such dosage forms.

The present disclosure provides sustained release compositions of (Z)-endoxifen and polymorphs and salts thereof and methods of making sustained release compositions of (Z)-endoxifen and polymorphs and salts thereof. The present disclosure also provides methods for treating disorders susceptible to (Z)-endoxifen, including hormone dependent disorders and mood disorders.

An alginate and stearic acid composition is described, including methods of molding it into tablets further comprising a drug, and methods of controlling the drug release from the tablets.

The instant application relates to the field of pharmaceutical compositions comprising dasatinb. Furthermore, the instant application relates to a method of treating proliferative disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said compositions.

The present invention is directed to a composition made of a microalgae powder, and a filler or a filler and magnesium. The composition may further include a wax material, an emulsifier, an antioxidant, or their combinations.

The present invention relates to a film-coated tablet having a high chemical stability of an active ingredient, said film-coated tablet comprising: (a) a tablet core containing obeticholic acid or a pharmaceutically acceptable salt thereof; and (b) a coating layer, which is provided on the surface of the tablet core, containing a film base and being substantially free from any plasticizer or containing at least one kind of specific plasticizer.

A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.

An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.